A randomised controlled trial to evaluate the effectiveness of Ganoderma lucidum for treatment of hyperglycemia in persons with metabolic syndrome

Phase 1

Completed

• Conditions: Metabolic syndrome; Metabolic and Endocrine - Normal metabolism and endocrine development and function

• Registration Number: ACTRN12606000485538
• Lead Sponsor: Allife Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-11-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

Must have hyperglycemia (FPG- Fasting Plasma Glucose over 6.1 mmol/L) and meet National Cholesterol Education Program- Adult Treatment Panel III criteria for metabolic syndrome.

Exclusion Criteria

Unstable health (recent or immediate future hospitalisation, surgery), recent history of hypoglycemic episodes, use insulin, history or organ transplant, liver or kidney disease, infection, pregnancy and allergy to mushrooms.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting plasma glucose[Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks];HbA1C (glycosylated haemoglobin)[Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks]

Secondary Outcome Measures

Name	Time	Method
Health related Quality of Life (SF-36)[Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks];Blood pressure[Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks];Blood triglycerides[Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks];Blood high density lipoproteins[Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks];Obesity[Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks]